RecallRadar

FDA Drug recall D-0222-2025

Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc.,…

On 2025-02-12 the FDA classified a Class III recall of Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc.,… by Pai Holdings, citing superpotent; sodium benzoate preservative.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0222-2025
ClassificationClass III
Statusterminated
Initiated2025-01-07
Published2025-02-12
Last updated2026-09-13 11:52 UTC
CompanyPai Holdings
DistributionOH

Product

Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc., Greenville, SC 29605, NDC 0121-0775-16

Reason

Superpotent; sodium benzoate preservative

Identifiers

ndc0121-0775-04
ndc0121-0775-08
ndc0121-0775-16
ndc0121-1775-05
ndc0121-1775-00
ndc0121-1775-10
ndc0121-1775-40
ndc0121-1550-10
ndc0121-1550-00
ndc0121-1550-40
code_infoLot number 4B07, Exp Date: 2026-OCT-31

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0222-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.